Santhera Pharmaceuticals Holding Valuation
Is SANNZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SANNZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SANNZ (CHF8.95) is trading below our estimate of fair value (CHF534.05)
Significantly Below Fair Value: SANNZ is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SANNZ?
Other financial metrics that can be useful for relative valuation.
| What is SANNZ's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CHF 107.87m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | 2.1x |
| PEG Ratio | 0.05x |
Price to Earnings Ratio vs Peers
How does SANNZ's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 60.6x | ||
BVXP Bioventix | 23.8x | 5.2% | UK£206.2m |
GNS Genus | 164.3x | 39.4% | UK£1.3b |
FENC Fennec Pharmaceuticals | 51.4x | 57.4% | US$132.7m |
C4XD C4X Discovery Holdings | 2.9x | -88.3% | UK£30.3m |
SANNZ Santhera Pharmaceuticals Holding | 1.7x | 35.4% | CHF 107.9m |
Price-To-Earnings vs Peers: SANNZ is good value based on its Price-To-Earnings Ratio (1.7x) compared to the peer average (60.6x).
Price to Earnings Ratio vs Industry
How does SANNZ's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Earnings vs Industry: SANNZ is good value based on its Price-To-Earnings Ratio (1.7x) compared to the European Biotechs industry average (27.3x).
Price to Earnings Ratio vs Fair Ratio
What is SANNZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 1.7x |
| Fair PE Ratio | 28.7x |
Price-To-Earnings vs Fair Ratio: SANNZ is good value based on its Price-To-Earnings Ratio (1.7x) compared to the estimated Fair Price-To-Earnings Ratio (28.7x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CHF 8.95 | CHF 32.00 +257.7% | 21.9% | CHF 39.00 | CHF 25.00 | n/a | 2 |
| Sep ’25 | CHF 9.01 | CHF 34.50 +282.9% | 13.0% | CHF 39.00 | CHF 30.00 | n/a | 2 |
| Aug ’25 | CHF 9.46 | CHF 34.50 +264.7% | 13.0% | CHF 39.00 | CHF 30.00 | n/a | 2 |
| Jul ’25 | CHF 8.67 | CHF 34.50 +297.9% | 13.0% | CHF 39.00 | CHF 30.00 | n/a | 2 |
| Jan ’25 | CHF 9.90 | CHF 71.00 +617.2% | 57.7% | CHF 112.00 | CHF 30.00 | n/a | 2 |
| Dec ’24 | CHF 9.69 | CHF 70.00 +622.4% | 60.0% | CHF 112.00 | CHF 28.00 | n/a | 2 |
| Nov ’24 | CHF 10.70 | CHF 70.00 +554.2% | 60.0% | CHF 112.00 | CHF 28.00 | n/a | 2 |
| Oct ’24 | CHF 8.16 | CHF 68.00 +733.3% | 64.7% | CHF 112.00 | CHF 24.00 | n/a | 2 |
| Sep ’24 | CHF 8.64 | CHF 68.00 +687.0% | 64.7% | CHF 112.00 | CHF 24.00 | CHF 9.01 | 2 |
| Aug ’24 | CHF 8.61 | CHF 68.00 +689.8% | 64.7% | CHF 112.00 | CHF 24.00 | CHF 9.46 | 2 |
| Feb ’24 | n/a | CHF 88.00 0% | 54.5% | CHF 136.00 | CHF 40.00 | CHF 9.40 | 2 |
| Jan ’24 | n/a | CHF 88.00 0% | 54.5% | CHF 136.00 | CHF 40.00 | CHF 9.90 | 2 |
| Sep ’23 | n/a | CHF 55.00 0% | 27.3% | CHF 70.00 | CHF 40.00 | CHF 8.64 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.